Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy

被引:33
|
作者
Lee, YJ
Galoforo, SS
Battle, P
Lee, H
Corry, PM
Jessup, JM
机构
[1] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA
[3] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48073 USA
[4] Univ Ulsan, Sch Med, Dept Microbiol, Seoul, South Korea
[5] Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA
关键词
heat shock promoter; p53; mutant; HSV-TK; E. coli CD; adenoviral vector; cytopathic effect;
D O I
10.1038/sj.cgt.7700310
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Tumor cells that express a fusion gene of Escherichia coli cytosine deaminase (CD) and herpes simplex virus type I thymidine kinase (TK) sequences activate and are subsequently killed by the nontoxic prodrugs 5-fluorocytosine and ganciclovir. We have previously developed a recombinant adenovirus containing the CD - TK fusion gene controlled by the human inducible heat shock protein 70 promoter so that heat at 41 degreesC for I hour induces therapeutic gene expression. This adenovirus effectively transduces heat-inducible expression of the CD-TK gene into human prostate carcinoma cells. However, because a limited number of cells in a tumor can actually be infected, we created a replicating adenoviral vector to increase CD-TK gene expression. This vector is a replication-competent, E1B-attenuated adenoviral vector containing the hsp70 promoter-driven CD-TK gene (Ad.E1A(+)HS-CDTK). When human prostate adenocarcinoma DU-145 cells (mutant p53) were infected with the virus at a multiplicity of infection (MOI) of I or 10, the viral replication was detected within 2 days at both MOIs. Similar results were observed in human colorectal carcinoma CX-I cells. When DU-145 cells were infected with the virus at an MOI of 10, incubated for 24 hours, heated at 41 degreesC for 4 hours and then harvested 20 hours later, Western blot analysis demonstrated that this virus successfully produced viral EIA proteins and heat shock stimulated the CD-TK gene expression by 12.3-fold. In addition, Ad.E1A(+)HS-CDTK effectively suppressed cell proliferation by viral cytopathic, effect). Unlike with a replication-incompetent virus (Ad.HS-CDTK), the cytopathic effect of the virus and cytotoxicity in the presence of the prodrugs were still observed even at low MOI (MOI=1.0).
引用
收藏
页码:397 / 404
页数:8
相关论文
共 50 条
  • [31] Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer
    Inoko, Kazuho
    Hiraoka, Kei
    Inagaki, Akihito
    Takahashi, Mizuna
    Kushibiki, Toshihiro
    Hontani, Koji
    Takano, Hironobu
    Sato, Shoki
    Takeuchi, Shintaro
    Nakamura, Toru
    Tsuchikawa, Takahiro
    Shichinohe, Toshiaki
    Gruber, Harry E.
    Jolly, Douglas J.
    Kasahara, Noriyuki
    Hirano, Satoshi
    CANCER GENE THERAPY, 2018, 25 (7-8) : 184 - 195
  • [32] Immunolocalization and adenoviral vector-mediated manganese superoxide dismutase gene transfer to experimental oral tumors
    Lam, EWN
    Hammad, HM
    Zwacka, R
    Darby, CJ
    Baumgardner, KR
    Davidson, BL
    Oberley, TD
    Engelhardt, JF
    Oberley, LW
    JOURNAL OF DENTAL RESEARCH, 2000, 79 (06) : 1410 - 1417
  • [33] Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer
    J Wang
    A Voutetakis
    C Zheng
    B J Baum
    Gene Therapy, 2004, 11 : 729 - 733
  • [34] Retroviral replicating vector-mediated prodrug activator gene therapy in an experimental model of human osteosarcoma
    Kubo, S.
    Takagi-Kimura, M.
    Kasahara, N.
    HUMAN GENE THERAPY, 2017, 28 (12) : A28 - A29
  • [35] Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer
    Kazuho Inoko
    Kei Hiraoka
    Akihito Inagaki
    Mizuna Takahashi
    Toshihiro Kushibiki
    Koji Hontani
    Hironobu Takano
    Shoki Sato
    Shintaro Takeuchi
    Toru Nakamura
    Takahiro Tsuchikawa
    Toshiaki Shichinohe
    Harry E Gruber
    Douglas J Jolly
    Noriyuki Kasahara
    Satoshi Hirano
    Cancer Gene Therapy, 2018, 25 : 184 - 195
  • [36] Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer
    Wang, J
    Voutetakis, A
    Zheng, C
    Baum, BJ
    GENE THERAPY, 2004, 11 (08) : 729 - 733
  • [37] Adenoviral vector-mediated manganese superoxide dismutase gene transfer to experimental oral tumors.
    Lam, EWN
    Zwacka, R
    Darby, CJ
    Engelhardt, JF
    Davidson, BL
    Oberley, LW
    FREE RADICAL BIOLOGY AND MEDICINE, 1998, 25 : S117 - S117
  • [38] Vector-mediated cancer gene therapy - An overview
    Seth, P
    CANCER BIOLOGY & THERAPY, 2005, 4 (05) : 512 - 517
  • [39] Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways
    Kushwah, R.
    Oliver, J. R.
    Cao, H.
    Hu, J.
    GENE THERAPY, 2007, 14 (16) : 1243 - 1248
  • [40] Remission of type I diabetes by adenoviral vector-mediated beta-cellulin gene therapy
    Shin, S
    Jun, HS
    Yoon, JW
    DIABETES, 2004, 53 : A384 - A385